NASDAQ:ARVN - Arvinas Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.50 -0.15 (-0.66 %) (As of 04/26/2019 09:40 AM ET)Previous Close$22.65Today's Range$22.50 - $22.6452-Week Range$10.19 - $25.61Volume901 shsAverage Volume147,198 shsMarket Capitalization$727.43 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut. Receive ARVN News and Ratings via Email Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN Previous Symbol CUSIPN/A CIKN/A Webwww.arvinas.com Phone203-535-1456Debt Debt-to-Equity Ratio0.01 Current Ratio8.52 Quick Ratio8.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.32 million Price / Sales50.80 Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book5.33Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares32,330,000Market Cap$727.43 million Next Earnings Date6/25/2019 (Estimated) OptionableNot Optionable Arvinas (NASDAQ:ARVN) Frequently Asked Questions What is Arvinas' stock symbol? Arvinas trades on the NASDAQ under the ticker symbol "ARVN." How were Arvinas' earnings last quarter? Arvinas Inc (NASDAQ:ARVN) announced its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.08. The business earned $3.44 million during the quarter, compared to analyst estimates of $3.38 million. View Arvinas' Earnings History. When is Arvinas' next earnings date? Arvinas is scheduled to release their next quarterly earnings announcement on Tuesday, June 25th 2019. View Earnings Estimates for Arvinas. What price target have analysts set for ARVN? 4 Wall Street analysts have issued 1 year target prices for Arvinas' shares. Their forecasts range from $17.00 to $23.00. On average, they anticipate Arvinas' stock price to reach $20.3333 in the next twelve months. This suggests that the stock has a possible downside of 9.6%. View Analyst Price Targets for Arvinas. What is the consensus analysts' recommendation for Arvinas? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas. Has Arvinas been receiving favorable news coverage? Media stories about ARVN stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Arvinas earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of Arvinas' key competitors? Some companies that are related to Arvinas include Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Reata Pharmaceuticals (RETA), Insmed (INSM), Arena Pharmaceuticals (ARNA), Mirati Therapeutics (MRTX), The Medicines (MDCO), PTC Therapeutics (PTCT), Uniqure (QURE), AnaptysBio (ANAB) and Nabriva Therapeutics (NBRV). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Krystal Biotech (KRYS), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Gemphire Therapeutics (GEMP), Genocea Biosciences (GNCA), Micron Technology (MU), Obalon Therapeutics (OBLN) and Rigel Pharmaceuticals (RIGL). Who are Arvinas' key executives? Arvinas' management team includes the folowing people: Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)Mr. Sean A. Cassidy, Chief Financial Officer (Age 49)Dr. Ian Taylor, Sr. VP of Biology (Age 57)Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardMr. Matthew Batters, Exec. Director of Alliance Management, Bus. Devel. & Corp. Counsel (Age 44) When did Arvinas IPO? (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. When did Arvinas' lock-up period expire? Arvinas' lock-up period expired on Tuesday, March 26th. Arvinas had issued 7,500,000 shares in its public offering on September 27th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. Since the end of Arvinas' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Arvinas' major shareholders? Arvinas' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Matisse Capital (0.11%). Company insiders that own Arvinas stock include Bradley Albert Margus, Ian Taylor, James E Flynn, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View Institutional Ownership Trends for Arvinas. Which major investors are selling Arvinas stock? ARVN stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital. View Insider Buying and Selling for Arvinas. How do I buy shares of Arvinas? Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arvinas' stock price today? One share of ARVN stock can currently be purchased for approximately $22.50. How big of a company is Arvinas? Arvinas has a market capitalization of $727.43 million and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. What is Arvinas' official website? The official website for Arvinas is http://www.arvinas.com. How can I contact Arvinas? Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected] MarketBeat Community Rating for Arvinas (NASDAQ ARVN)Community Ranking: 1.9 out of 5 ()Outperform Votes: 21 (Vote Outperform)Underperform Votes: 35 (Vote Underperform)Total Votes: 56MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: What is a growth and income fund?